New trials, publications, preprints and grants on this target, month by month.
Publication
TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS.
3 Nov 2026· Cancer immunology research· PUBMED
Publication
TIM-3 Up-regulation Is Associated With Altered Cytotoxic Function of Allogeneic Vγ9Vδ2 T Cells in Urinary Bladder Cancer.
1 Nov 2026· Anticancer research· PUBMED
Publication
TIM-3 Functions as an Activator of NK Cells in GBM and Can Be Upregulated by Torin-1: Implications for Exogenous NK Cell Transplantation.
23 Oct 2026· Immunology· PUBMED
Publication
Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer.
14 Oct 2026· Frontiers in immunology· PUBMED
Publication
Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder.
5 Oct 2026· Frontiers in immunology· PUBMED
Publication
Low-dose antiangiogenic multikinase inhibitor AL3810 synergizes with PD-1 blockade by reducing CSF1-driven MHC-IIint tumour-associated macrophages to optimize TIM-3+ CD8+ T-cell effector function.
28 Sept 2026· British journal of pharmacology· PUBMED
Publication
Serine protease inhibitor from Trichinella spiralis ameliorates diet-induced obesity and adipose tissue inflammation through TIM-3-dependent macrophage reprogramming.
25 Sept 2026· PLoS pathogens· PUBMED
Publication
Lnc-TIM3 promotes acute lymphoblastic leukemia progression through miR-5094-mediated regulation of TIM3.
28 Aug 2026· Translational cancer research· PUBMED
Publication
TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue.
28 Aug 2026· Clinical immunology (Orlando, Fla.)· PUBMED
Publication
Association of serum TIM-3 and Galectin-9 levels with glaucoma progression: implications for clinical monitoring.
15 Aug 2026· American journal of translational research· PUBMED
Publication
TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.
12 Aug 2026· Nature cancer· PUBMED
Publication
TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2-like macrophages induced by tumor microenvironment-derived TGFβ1.
5 Aug 2026· The Journal of pathology· PUBMED
Publication
NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma.
3 Jul 2026· Cancer immunology, immunotherapy : CII· PUBMED
Publication
The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion.
2 Jul 2026· Human immunology· PUBMED
Publication
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
19 Jun 2026· Journal for immunotherapy of cancer· PUBMED
Publication
TIM-3 as an immune and leukemia stem-cell biomarker in acute myeloid leukemia: diagnostic laboratory and translational perspectives.
17 Jun 2026· Clinica chimica acta; international journal of clinical chemistry· PUBMED
Publication
PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression.
16 Jun 2026· Oncology research· PUBMED
Publication
Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.
7 Jun 2026· Transfusion medicine reviews· PUBMED
Publication
The expression status and clinical value of TIM-3 in intrahepatic cholangiocarcinoma.
5 Jun 2026· BMC cancer· PUBMED
Publication
The Signaling Networks of TIM-3, TGF-β, and STING in Glioblastoma.
28 May 2026· Cells· PUBMED
Publication
The implications of TMSB4X in TIM3 hypermethylation and CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
23 May 2026· Scientific reports· PUBMED
Publication
TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal.
19 May 2026· Cancer cell international· PUBMED
Publication
TIM-3-dependent lysosome biogenesis is required for myelin debris clearance in macrophages.
12 May 2026· Brain : a journal of neurology· PUBMED
Preprint
TIM3 + Tumor Associated M2 Macrophages Impair Antitumor T Cell Immunity and Promote Gastric Cancer Progression and Peritoneal Metastasis.
17 Apr 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer.
10 Apr 2026· Journal of translational medicine· PUBMED
Publication
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.
10 Apr 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Soluble TIM-3 and galectin-9 serve as additional diagnostic biomarkers in primary central nervous system lymphoma.
2 Apr 2026· Journal of neurology· PUBMED
Publication
TIM-3 in AML: pathogenic roles and therapeutic targetability.
2 Apr 2026· Clinical and experimental medicine· PUBMED
Publication
Regulatory Effect of Moxibustion on Macrophage Polarization and Migration in RA Model Rats and the Role of TIM-3.
27 Mar 2026· Journal of visualized experiments : JoVE· PUBMED
Publication
Increased LAG-3, TIM-3, and IDO1 Expression Is Associated With Oral Squamous Cell Carcinoma in Never Smokers and Never Drinkers.
19 Mar 2026· Oral diseases· PUBMED